Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case–control and a case–case comparison by Ma, Huiyan et al.
Open Access
Available online http://breast-cancer-research.com/content/8/4/R39
Page 1 of 10
(page number not for citation purposes)
Vol 8 No 4 Research article
Hormone-related risk factors for breast cancer in women under 
age 50 years by estrogen and progesterone receptor status: 
results from a case–control and a case–case comparison
Huiyan Ma1, Leslie Bernstein1, Ronald K Ross1 and Giske Ursin1,2
1Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, USC/Norris Comprehensive 
Cancer Center, Los Angeles, California 90089-9175, USA
2Department of Nutrition, University of Oslo, Norway
Corresponding author: Giske Ursin, gursin@usc.edu
Received: 28 Mar 2006 Revisions requested: 16 May 2006 Revisions received: 8 Jun 2006 Accepted: 20 Jun 2006 Published: 17 Jul 2006
Breast Cancer Research 2006, 8:R39 (doi:10.1186/bcr1514)
This article is online at: http://breast-cancer-research.com/content/8/4/R39
© 2006 Ma et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction It has been suggested that hormonal risk factors
act predominantly on estrogen receptor and progesterone
receptor (ER/PR)-positive breast cancers. However, the data
have been inconsistent, especially in younger women.
Methods We evaluated the impact of age at menarche,
pregnancy history, duration of breastfeeding, body mass index,
combined oral contraceptive use, and alcohol consumption on
breast cancer risk by ER/PR status in 1,725 population-based
case patients and 440 control subjects aged 20 to 49 years
identified within neighborhoods of case patients. We used
multivariable unconditional logistic regression methods to
conduct case–control comparisons overall as well as by ER/PR
status of the cases, and to compare ER+PR+ with ER-PR- case
patients.
Results The number of full-term pregnancies was inversely
associated with the risk of ER+PR+ breast cancer (ptrend =
0.005), whereas recent average alcohol consumption was
associated with an increased risk of ER+PR+ breast cancer
(ptrend = 0.03). Neither of these two factors was associated with
the risk of ER- PR- breast cancer. Late age at menarche and a
longer duration of breastfeeding were both associated with
decreased breast cancer risk, irrespective of receptor status (all
ptrend≤ 0.03).
Conclusion Our results suggest that the number of full-term
pregnancies and recent alcohol consumption affect breast
cancer risk in younger women predominantly through estrogen
and progesterone mediated by their respective receptors. Late
age at menarche and breastfeeding may act through different
hormonal mechanisms.
Introduction
It has been well documented that estrogen and progesterone
are important in breast tumorigenesis [1-3], and their effects
on the breast are mediated by their respective receptors, the
estrogen receptor (ER) and the progesterone receptor (PR)
[4-7]. Furthermore, it has been hypothesized that hormone-
related risk factors that reflect exposure to estrogen and pro-
gesterone may be predominantly associated with breast
tumors that express ER and PR, but not with those lacking ER
and PR expression [8-14]. Several epidemiological studies
have examined this hypothesis by ER and PR status separately
or jointly [15-17], and a review from 2004 [17] concluded that
early age at menarche, nulliparity, and delayed childbearing
were associated with an increased risk for receptor-positive
breast cancer, but not with receptor-negative breast cancer.
However, in the prospective data from the Nurses' Health
Study [18], the adverse effect of nulliparity was confined to
ER+PR+ breast cancer, but early age at menarche was associ-
ated with an increased risk of both ER+PR+ and ER- PR- breast
cancer and the adverse effect of delayed childbearing was
observed for ER- PR- but not ER+PR+ breast cancer. Results
from studies of young women under the age of 50 years [19-
21] or premenopausal women [12,22] are even less consist-
ent. To help shed light on the issue, we evaluated hormone-
related risk factors for breast cancer by receptor subtypes
(ER+PR+ and ER- PR-) in a large study of women aged 20 to
BMI = body mass index; CARE = Contraceptive and Reproductive Experiences; CI = confidence interval; COC = combination oral contraceptive; 
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49 years, using both case–control and case–case compari-
sons.
Materials and methods
Case patients
Case patients were identified through the Los Angeles County
Cancer Surveillance Program (CSP), the population-based
cancer registry that is part of the National Cancer Institute's
Surveillance, Epidemiology, and End Results (SEER) cancer
registry program. Eligible case patients were US-born English-
speaking, white (including Hispanic) or African-American,
female residents of Los Angeles County aged 20 to 49 years
when diagnosed with histologically confirmed first primary
invasive breast cancer. We identified 2,882 eligible case
patients (2,534 white and 348 African-American). White
patients were diagnosed between February 1998 and May
2003 and African-American patients were diagnosed between
January 2000 and May 2003. We were unable to interview
1,088 of the 2,882 eligible case patients (38%) because of
patient refusal (n  = 428), no longer living in Los Angeles
County (n = 37), inability to be located (n = 88), death (n =
38), serious illness or disability (n = 18), physician refusal (n =
50), or inability to schedule the interview within 18 months of
diagnosis (n  = 429). We successfully interviewed 1,794
(62%) eligible case patients (1,585 white, 209 African-Amer-
ican).
Control subjects
Because this study was originally designed as a case–case
study to examine genetic risk factors for breast cancer, we did
not collect control subjects for all case patients. The control
subjects who were recruited were matched by race and age
(within 5 years and aged 20 to 49 years) to a subset of case
patients who were diagnosed between July 2000 and March
2003. Control subjects were US-born English-speaking white
or African-American women who had never been diagnosed
with invasive or in situ breast cancer. They were identified by
using a neighborhood walk algorithm that we had used in pre-
vious case–control studies [23,24]. Field staff conducted
walks according to a predefined pattern in the neighborhoods
where case patients lived at the time of their diagnoses. The
houses on the immediate blocks surrounding the home of the
case patients were excluded from the walk. Residences were
visited sequentially and information on potentially eligible
women was obtained. If no one was home at the time of the
visit, we left a request for information at the door, and we
sought further information from neighbors so that we could
contact the residents later. If we received no response to our
written request, we sent additional letters until we were able to
determine whether an eligible woman lived at the address in
question. Detailed records were maintained to determine the
number of housing units contacted in order to identify and
interview a control subject. By the end of the study we had
identified 603 eligible control subjects for the 1,108 case
patients (1,018 white, 90 African-American). We were unable
to interview 159 of the 603 control subjects (26%) as a result
of subject refusal (n = 77), no longer living in Los Angeles
County (n = 18), death (n = 1), serious illness (n = 2), or ina-
bility to schedule the interview within 18 months from the date
of initial household contact (n = 61). We successfully inter-
viewed 444 (74%) of eligible control subjects (409 white, 35
African-American). On average, 20 houses were canvassed to
find an eligible control subject who agreed to be interviewed.
Data collection
All participants were interviewed in person with the use of a
structured questionnaire, which was a modified version of the
questionnaire used for the Women's Contraceptive and
Reproductive Experiences (CARE) Study [25]. Our question-
naire included reproductive history (including breastfeeding),
detailed histories of oral contraceptive use and alcohol con-
sumption, family breast cancer history, demographics, and
other factors. Information was recorded up to a predetermined
reference date for each participant. The reference date was
the date of diagnosis for case patients and the date of initial
household contact for control subjects. All participants signed
informed consent documents before interview. The study pro-
tocol was approved by the federally approved Institutional
Review Board at the University of Southern California Medical
Center.
Information on ER and PR status for interviewed case patients
was obtained from the CSP. Among the 1,794 case patients,
1,510 (84%) had information on both ER and PR status; 91 of
these were reported as weakly or borderline positive (84
cases) or undecided (7 cases) for either ER or PR. Among the
other 1,419 case patients, 881 (62%) were ER+PR+, 92 (6%)
were ER+PR-, 41 (3%) were ER- PR+, and 405 (29%) were
ER- PR- .
Data analyses
We compared demographic and hormone-related risk factors
among case patients with known ER and PR information, bor-
derline positive or undecided results, and patients without ER
or PR information, with the use of F tests for differences in
means and Pearson χ2 tests for differences in frequency distri-
butions. When the two-sided p  value comparing all three
groups was less than 0.05, we also performed pairwise com-
parisons by using Bonferroni t  tests or Pearson χ2 tests,
imposing a Bonferroni correction to the p value, restricting the
overall type I error to 5% by setting as statistically significant
only two-sided p values less than 0.017 for each pairwise
comparison [26].
Analyses were conducted to assess the association between
breast cancer and the following factors: age at menarche,
number of full-term (greater than 26-week gestation) pregnan-
cies, age at first full-term pregnancy (defined for each woman
as the age at which that pregnancy ended), duration of breast-
feeding, body mass index (BMI, kg/m2) one year before theAvailable online http://breast-cancer-research.com/content/8/4/R39
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participant's reference date, duration of combined oral contra-
ceptive (COC) use, alcohol drinking status during reference
age (never, former, and current – that is, drinking alcohol dur-
ing reference age), and the average number of alcoholic drinks
per week in the 5-year period that ended 2 years before the
reference age. One alcoholic drink was defined as 12 ounces
(355 ml) of beer, 4 ounces (118 ml) of wine, or 1.5 ounces (44
ml) of liquor.
We conducted case–control comparisons for overall,
ER+PR+, and ER- PR- case patients with control subjects, and
also compared ER+PR+ with ER- PR- case patients. We used
polytomous logistic regression [27] to compare ER+PR+ and
ER- PR- case patients simultaneously with control subjects.
We used a multivariable unconditional logistic regression
approach [27] for the comparisons of all case patients with
controls, and ER+PR+ with ER- PR- case patients. We esti-
mated multivariable adjusted odds ratios (ORs) and 95% con-
fidence intervals (CIs). Tests for trend were conducted by
fitting ordinal values corresponding to categories of exposure
in our models and testing whether the coefficient (slope of the
dose response) differed from zero.
Adjustment was made for race (white, African-American), age
(less than 30, 30 to 34, 35 to 39, 40 to 44, 45 to 49 years),
and education (high school or lower, technical school or some
college, college graduate) in all our models. Additionally, mul-
tivariable models included variables selected a priori as poten-
tial confounders: first-degree family history of breast cancer
(no first-degree family history, mother or sister with breast can-
cer, unknown first-degree family history), age at menarche (11
or less, 12, 13, at least 14 years), gravidity (never pregnant,
ever pregnant), number of full-term pregnancies (never full-
term pregnant, one, two, three, at least four full-term pregnan-
cies), BMI 1 year before reference date (less than 25, 25 to
29, 30 to 34, at least 35 kg/m2), COC use (never, less than 1,
1 to 4, 5 to 9, at least 10 years), the average number of alco-
holic drinks per week in the recent 5 years (never, less than 3,
3 to 5, 6 to 11, at least 12 drinks, drinking alcohol but not
within the 5 years of interest), and a three-category variable
combining menopausal status and hormone therapy use (pre-
menopausal or – among postmenopausal women – never
used hormone therapy, or had used estrogen therapy or estro-
gen plus progestin therapy). When estimating the effects of
parity or restricting analyses to parous women, we did not
include gravidity in our models. A single model was fitted to
assess the joint effects of age at first full-term pregnancy (less
than 22, 22 to 27, 28 to 31, at least 32 years) and breastfeed-
ing duration (0, less than 1, 1 to 6, 7 to 23, at least 24 months)
among parous women. All variables were included as categor-
ical variables in the models. In reporting the results of trend
tests, we considered a two-sided p value of less than 0.05 as
statistically significant. All analyses were performed with the
SAS statistical package (Version 9.0, SAS Institute, Cary, NC,
USA).
To maintain a constant sample size for all analyses, we
excluded 69 case patients and 4 control subjects for the fol-
lowing reasons: missing information on educational attainment
(15 cases and 1 control), age at menarche (3 cases), parity (4
cases and 1 control), duration of breastfeeding (6 cases), BMI
(4 cases), duration of COC use (17 cases and 1 control),
recent alcohol consumption (14 cases); missing information
on two or more of these factors (6 cases and 1 control). This
resulted in 1,725 case patients and 440 control subjects avail-
able for the overall case–control analyses. Among the 1,725
case patients, 1,449 (84%) had information on both ER and
PR status; 83 of these were reported as weakly, borderline
positive or undecided for either ER or PR and were excluded
from the analyses by receptor subtypes. Among the other
1,366 case patients, 63% were ER+PR+, 6% were ER+PR-,
3% were ER-PR+, and 28% were ER- PR- . The frequency dis-
tribution across receptor subtypes was similar to those
reported by previous studies conducted within the SEER reg-
istries [21,28]. In addition, our numbers are very similar to
those that we observed among the white Los Angeles cases
in the Women's CARE Study. This may be the most appropri-
ate comparison, because 88% of the cases in the present
study were white. We excluded ER+PR- and ER- PR+ subtypes
from the analyses by receptor status because they were rare.
There were therefore 1,239 remaining for the analyses by ER
and PR status (854 ER+PR+ and 385 ER- PR-).
As described above, our control subjects were identified
through matching to a subset of the cases. An alternative to
conditional logistic regression in matched studies with dispro-
portionate numbers of cases and controls is to break the
match and conduct unconditional logistic regression with
detailed adjustment for the matching factors [29]. We con-
ducted both detailed stratified analyses, with strata defined by
race, age categories (five-year categories) and education as a
proxy of socioeconomic status/neighborhood as well as
standard unconditional logistic regression with adjustment for
the same factors. Because the results remained the same, we
chose to use multivariable unconditional logistic regression for
all our analyses. We also repeated all the analyses with the
subset of the cases used to identify the controls. Again, the
results were essentially identical with the overall analyses; we
therefore present results based on all case patients.
Results
Table 1 shows the distributions of demographic and hormone-
related risk factors among case patients stratified by availabil-
ity of ER/PR information and among control subjects. Age at
breast cancer diagnosis (pF  test = 0.0001), education level
(  = 0.01), age at first full-term pregnancy (pF test = 0.002),
and percentage of case patients who ever breastfed (  =
0.01) differed across the three case groups. Pairwise analyses
revealed that the differences were between case patients with
pχ 2
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Table 1
Demographic and hormone-related risk factors
Variables Cases by availability of ER/PR information Controls
Cases with known 
receptor status
Cases with borderline 
positive/undecided status
Cases without information p for comparison across 
the three case groups
Number of subjects 1,366 (79.2%) 83 (4.8%) 276 (16.0%) 440
Mean age at reference date (SD), years 42.5 (5.4) 42.8 (5.2) 44.0 (4.6) 0.0001a,b 42.6 (4.9)
Race
White 1,206 (88.3%) 77 (92.8%) 238 (86.2%) 405 (92.0%)
African-American 160 (11.7%) 6 (7.2%) 38 (13.8%) 0.26c 35 (8.0%)
Education
High school or lower 262 (19.2%) 19 (22.9%) 76 (27.5%) 60 (13.6%)
Technical school or some college 489 (35.8%) 28 (33.7%) 103 (37.3%) 150 (34.1%)
College graduate 615 (45.0%) 36 (43.4%) 97 (35.2%) 0.01c,d 230 (52.3%)
First-degree breast cancer family 
history
No 1,091 (79.9%) 63 (75.9%) 224 (81.1%) 388 (88.2%)
Yes 229 (16.7%) 19 (22.9%) 46 (16.7%) 41 (9.3%)
Unknowne 46 (3.4%) 1 (1.2%) 6 (2.2%) 0.39c 11 (2.5%)
Mean age at menarche (SD), years 12.4 (1.5) 12.6 (1.7) 12.4 (1.4) 0.51a 12.7 (1.5)
Ever had a full-term (>26-week) 
pregnancy
66.6% 74.7% 68.5% 0.28c 71.6%
Mean number of full-term pregnancies 
(SD)
2.1 (1.0) 2.1 (1.1) 2.1 (0.9) 0.92a 2.2 (1.1)
Mean age at first full-term pregnancy 
(SD)
26.7 (6.4) 26.2 (6.2) 24.9 (5.8) 0.002a,b 27.1 (6.2)
Ever breastfed among parous women 80.4% 77.4% 70.9% 0.01c,d 87.9%
Mean duration of breastfeeding (all 
pregnancies) among those who 
breastfed (SD), months
14.2 (16.3) 13.7 (13.6) 12.6 (14.6) 0.56a 16.6 (17.3)
Mean BMI 1 year before reference date 
(SD), kg/m2
25.8 (6.1) 26.2 (6.4) 26.6 (6.5) 0.12a 25.7 (6.4)
Ever used COC 85.9% 84.3% 85.9% 0.92c 89.3%
Mean duration of COC use among 
users (SD), years
6.9 (6.3) 5.8 (6.6) 6.4 (6.4) 0.23a 6.7 (6.2)
Alcohol drinking status during reference 
age
Never 428 (31.3%) 34 (41.0%) 96 (37.8%) 141 (32.1%)
Former 259 (19.0%) 16 (19.3%) 53 (19.2%) 90 (20.5%)
Current 679 (49.7%) 33 (39.7%) 127 (46.0%) 0.30c 209 (47.5%)
Alcohol drinking status in recent 5-year 
period
No 428 (31.3%) 34 (41.0%) 96 (34.8%) 141 (32.1%)
Yes 759 (55.6%) 40 (48.2%) 137 (49.6%) 228 (51.8%)
Yes, but not in the five year period 179 (13.1%) 9 (10.8%) 43 (15.6%) 0.17c 71 (16.1%)
Mean number of alcoholic drinks per 
week in recent 5 years for drinkers (SD)
6.6 (20.1) 4.9 (6.1) 6.0 (8.4) 0.80a 4.6 (9.1)Available online http://breast-cancer-research.com/content/8/4/R39
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known ER/PR status and those without ER/PR information. In
comparison with case patients without ER/PR information,
case patients with known ER/PR status were on average 1.5
years younger at diagnosis (pt test <0.0001), better educated
(  = 0.001), on average 1.8 years older at first full-term
pregnancy (pt test = 0.001), and had a higher percentage of
case patients who had breastfed (  = 0.004).
Age at menarche
Age at menarche was negatively associated with breast can-
cer risk regardless of ER/PR status (all ptrend≤ 0.008; Table 2).
In comparison with women who had menarche before the age
of 12 years, later age at menarche (at least 14 years) was
associated with an approximately 40% reduced risk of breast
cancer among the ER+PR+  case patients, ER-  PR-  case
patients, and all case patients combined. The associations
with age at menarche did not differ between ER+PR+ and ER-
PR- case patients (ptrend = 0.85).
Parity
A protective effect of parity was confined to women with
ER+PR+ breast cancer (Table 2). The OR of ER+PR+ breast
cancer decreased with increasing number of full-term preg-
nancies (ptrend = 0.005). Parous women who had four or more
full-term pregnancies had an approximately 50% reduction in
the risk of ER+PR+ breast cancer compared with women who
never had a full-term pregnancy. ER+PR+ case patients were
less likely to have had many full-term pregnancies than ER- PR-
case patients (ptrend = 0.09).
Age at first full-term pregnancy
A slight increase in risk for ER+PR+ breast cancer and a
reduced risk for ER- PR- breast cancer was observed with
increasing age at first full-term pregnancy, but none of the con-
fidence limits for the risk estimates excluded 1.0 and no linear
trend in risk was observed for either cancer type (ER+PR+,
ptrend = 0.49; ER- PR-, ptrend = 0.08; Table 2). ER+PR+ case
patients were more likely to have had a late first full-term preg-
nancy than ER-PR- case patients (ptrend = 0.009).
Breastfeeding
Duration of breastfeeding was negatively associated with
breast cancer risk regardless of ER/PR status (all ptrend≤ 0.03;
Table 2). In the case–case analysis, duration of breastfeeding
was not associated with ER/PR status (ptrend = 0.63).
Body mass index 1 year before reference date
Increasing BMI was associated with a non-statistically signifi-
cant decreasing risk of ER+PR+ breast cancer (ptrend = 0.20)
but was not associated with ER- PR- breast cancer (Table 2).
Moreover, among premenopausal women, increasing BMI was
marginally statistically significantly associated with a decreas-
ing risk of ER+PR+ breast cancer (ptrend = 0.08) but not ER-PR-
breast cancer (ptrend = 0.54). In comparison with premenopau-
sal women who had a low BMI (less than 25 kg/m2), the OR
among premenopausal women in the highest BMI category (at
least 35 kg/m2) was 0.58 (95% CI 0.34 to 1.00) for ER+PR+
breast cancer and 1.07 (95% CI 0.58 to 1.97) for ER- PR-
breast cancer. ER+PR+ case patients were less likely to have
had a higher BMI than ER- PR- case patients (ptrend = 0.005).
Combined oral contraceptive use
COC use was not associated with risk of either ER+PR+ or ER-
PR- breast cancer (Table 2). Women who had used COC for
10 years or longer had a slightly higher OR of ER- PR- breast
cancer (OR 1.27, 95% CI 0.75 to 2.14) but a lower OR of
ER+PR+ breast cancer (OR 0.76, 95% CI 0.49 to 1.18) com-
pared with never users. ER+PR+ case patients were less likely
to have had longer duration of COC use than ER- PR- case
patients (ptrend = 0.008).
Alcohol consumption
Alcohol drinking status during reference age was not associ-
ated with breast cancer risk (Table 2). However, the average
number of alcoholic drinks per week in the recent 5 years was
positively associated with ER+PR+  breast cancer (ptrend  =
0.03), weakly associated with all types of cancer together
(ptrend = 0.12), and not associated with ER- PR- breast cancer
(ptrend = 0.42). Overall, ER+PR+ case patients seemed more
likely to have drunk larger quantities of alcohol than ER- PR-
case patients, but the difference was not statistically signifi-
cant (ptrend = 0.23).
Discussion
Overall in this study of women under age 50 years, we found
associations that differed by ER/PR status for the number of
full-term pregnancies, recent alcohol consumption, and possi-
bly age at first full-term pregnancy and BMI. Risk reductions
associated with late age at menarche and long duration of
breastfeeding did not differ by ER/PR status. COC use was
not associated with breast cancer risk in this study.
The magnitude of the protective effect from multiple full-term
pregnancies for ER+PR+ breast cancer in our study is similar
pχ 2
pχ 2
Results are for 1,725 case patients and 440 control subjects. BMI, body mass index; COC, combined oral contraceptive; ER/PR, estrogen receptor 
and progesterone receptor; SD, standard deviation. aF test. bBonferroni t tests for pairwise comparisons: p values for cases with complete ER/PR 
information versus cases without ER/PR information ≤ 0.001, and p values for the other comparisons ≥ 0.20. cPearson χ2 test. dPearson χ2 tests for 
pairwise comparisons: p values for cases with complete ER/PR information versus cases without ER/PR information ≤ 0.004, and p values for the 
other comparisons ≥ 0.32. eUnknown category was excluded from Pearson χ2 tests.
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Table 2
Adjusted ORs for breast cancer associated with hormone-related risk factors by ER/PR status
Variables No. controls All cases versus controls ER+PR+ cases versus controls ER- PR- cases versus controls ER+PR+ cases 
versus ER- PR- 
cases
Number of cases OR (95% CI) Number of cases OR (95% CI) Number of cases OR (95% CI) OR (95% CI)
Age at menarche, years
≤ 11 90 400 1.00 188 1.00 92 1.00 1.00
12 109 532 1.13 (0.83–1.55) 278 1.24 (0.88–1.75) 119 1.18 (0.79–1.77) 1.04 (0.74–1.47)
13 121 475 0.88 (0.65–1.21) 231 0.87 (0.62–1.24) 110 0.94 (0.62–1.41) 0.93 (0.65–1.33)
≥ 14 120 318 0.61 (0.44–0.85) 157 0.60 (0.42–0.86) 64 0.59 (0.38–0.92) 1.02 (0.67–1.53)
Trend p value 0.0007 0.0006 0.008 0.85
Number of full-term pregnanciesa
None 125 564 1.00 301 1.00 113 1.00 1.00
1 85 347 0.91 (0.66–1.25) 157 0.77 (0.55–1.10) 82 1.06 (0.70–1.62) 0.70 (0.49–1.02)
2 139 492 0.81 (0.61–1.07) 251 0.77 (0.57–1.06) 106 0.95 (0.64–1.39) 0.84 (0.60–1.18)
3 56 224 0.81 (0.56–1.18) 100 0.69 (0.45–1.04) 54 1.06 (0.65–1.73) 0.68 (0.44–1.05)
≥ 4 35 98 0.49 (0.31–0.78) 45 0.47 (0.28–0.80) 30 0.72 (0.39–1.33) 0.65 (0.37–1.15)
Trend p value 0.008 0.005 0.50 0.09
Age at first full-term pregnancy for parous women, yearsa,b
<22 68 316 1.00 126 1.00 96 1.00 1.00
22–27 89 333 1.07 (0.72–1.58) 149 1.14 (0.73–1.78) 81 0.92 (0.56–1.50) 1.25 (0.81–1.94)
28–31 78 265 1.03 (0.66–1.60) 134 1.17 (0.71–1.93) 57 0.82 (0.46–1.45) 1.42 (0.85–2.37)
≥ 32 80 247 0.92 (0.57–1.48) 144 1.23 (0.72–2.10) 38 0.56 (0.30–1.07) 2.22 (1.24–3.98)
Trend p value 0.65 0.49 0.08 0.009
Duration of breastfeeding for parous women, monthsa,b
0 38 247 1.00 102 1.00 63 1.00 1.00
<1 23 144 0.99 (0.56–1.77) 65 1.01 (0.53–1.90) 38 1.19 (0.59–2.39) 0.82 (0.47–1.44)
1–6 80 273 0.58 (0.37–0.91) 131 0.57 (0.34–0.94) 68 0.72 (0.41–1.27) 0.77 (0.47–1.26)
7–23 110 322 0.52 (0.33–0.82) 165 0.52 (0.31–0.87) 63 0.55 (0.31–0.98) 0.97 (0.59–1.61)
≥ 24 64 175 0.51 (0.30–0.86) 90 0.49 (0.27–0.87) 40 0.62 (0.32–1.21) 0.77 (0.42–1.39)
Trend p value 0.001 0.002 0.03 0.63
BMI 1 year before reference date, kg/m2
<25 257 939 1.00 495 1.00 183 1.00 1.00
25–29 95 425 1.18 (0.89–1.55) 209 1.11 (0.82–1.50) 101 1.41 (0.99–2.02) 0.81 (0.59–1.10)
30–34 51 221 1.01 (0.70–1.44) 94 0.88 (0.59–1.30) 61 1.43 (0.91–2.23) 0.60 (0.40–0.89)
≥ 35 37 140 0.88 (0.58–1.34) 56 0.69 (0.43–1.11) 40 1.18 (0.70–2.01) 0.61 (0.38–0.99)
Trend p value 0.82 0.20 0.16 0.005
Duration of COC use, years
Never 47 244 1.00 128 1.00 47 1.00 1.00
<1 73 295 0.78 (0.51–1.18) 133 0.70 (0.44–1.12) 59 0.76 (0.43–1.33) 0.93 (0.57–1.52)
1–4 108 429 0.80 (0.54–1.19) 227 0.81 (0.53–1.25) 90 0.87 (0.52–1.46) 0.92 (0.59–1.43)
5–9 115 362 0.62 (0.42–0.93) 173 0.57 (0.37–0.88) 90 0.82 (0.49–1.37) 0.71 (0.45–1.12)
≥ 10 97 395 0.84 (0.56–1.26) 193 0.76 (0.49–1.18) 99 1.27 (0.75–2.14) 0.61 (0.39–0.96)Available online http://breast-cancer-research.com/content/8/4/R39
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to that observed in a previous study of young women [21],
smaller than that observed in a study of premenopausal
women (OR 0.44, 95% CI 0.26 to 0.75 of ER+PR+ cancer for
women having three or more live births compared with nullipa-
rous women) [22], and greater than that in two studies of
women under 45 years of age that did not find any associa-
tions with either receptor subtype [19,20]. A greater number
of full-term pregnancies may protect against receptor-positive
breast cancer by causing the full differentiation of breast epi-
thelium [30], thereby reducing cyclical morphological change
in breast tissue during the menstrual cycles [31].
Our results on age at first full-term pregnancy are consistent
with the bulk of the evidence that early age at first full-term
pregnancy is not a strong protective factor in young women.
This may be due to a transient increase in breast cancer risk
after pregnancy [32]. However, if early age at first full-term
pregnancy protects against any subtype of breast cancer, our
results suggest that it would be the receptor-positive cancer.
Five previous studies have examined the effect of BMI accord-
ing to ER/PR status among young [19,20] or premenopausal
[12,22,33] women. Two found that, when compared with the
lowest category of BMI, the highest category of BMI was asso-
ciated with a 23 to 29% reduction in risk of ER+PR+ breast
cancer but not ER- PR- breast cancer [19,22]. The other three
studies found no statistically significant association with any
receptor subtype [12,20,33]. Our data showed a 31%
reduced risk of ER+PR+ breast cancer, which did not quite
reach statistical significance. A possible mechanism that
would explain a protective effect of BMI on receptor-positive
tumors is that high BMI results in anovulatory menstrual cycles
with reduced exposure to ovarian hormones [34,35].
Among five previous epidemiological studies that examined
the effect of alcohol consumption according to ER/PR status
among young women [19,36] or premenopausal women
[12,22,37], two found a 10 to 38% increase in risk of ER+PR+
cancer, which was not statistically significant, for women at the
highest category of alcohol consumption versus women who
had never drunk alcohol [22,37]; one found an increase in risk
of the ER+PR- subtype [36]; and another found a non-statisti-
cally significant increase in risk of both ER+PR+ and ER- PR-
receptor subtypes [19]. Our effect estimate for alcohol con-
sumption was higher than those reported previously, possibly
because our women drinkers consumed greater amounts of
alcohol. Experimental [38] and cross-sectional [39] data have
shown that alcohol consumption may result in an increase in
blood estrogen levels among premenopausal women. Our
results are consistent with the hypothesis that alcohol exerts
its effect on the premenopausal breast via estrogen.
Our finding that late age at menarche is associated with a
reduced risk of both ER+PR+ and ER- PR- breast cancer is con-
sistent with two [19,20] of four previous case–control studies
conducted among women under 45 years [19,20] or premen-
opausal women [12,22]. The magnitude of the risk reduction
in the two previous studies ranged from 20 to 40% for women
with the oldest versus the youngest ages at menarche [19,20].
The protective effects of breastfeeding on both receptor-pos-
Trend p value 0.30 0.16 0.18 0.008
Alcohol drinking status during reference agec
Never 141 558 1.00 251 1.00 138 1.00 1.00
Former 90 328 0.96 (0.71–1.31) 162 1.02 (0.72–1.44) 74 0.88 (0.59–1.33) 1.14 (0.79–1.64)
Current 209 839 1.05 (0.81–1.36) 441 1.17 (0.88–1.55) 173 0.93 (0.67–1.30) 1.25 (0.93–1.68)
Average number of alcoholic drinks per week in recent 5 years
Never 141 558 1.00 251 1.00 138 1.00 1.00
<3 130 481 1.01 (0.76–1.35) 248 1.11 (0.81–1.53) 101 0.89 (0.61–1.30) 1.22 (0.87–1.71)
3–5 49 171 0.93 (0.63–1.37) 90 1.01 (0.66–1.54) 34 0.76 (0.45–1.28) 1.31 (0.81–2.11)
6–11 32 157 1.16 (0.75–1.81) 82 1.26 (0.78–2.03) 34 1.06 (0.60–1.86) 1.20 (0.74–1.94)
> 12 17 127 1.77 (1.01–3.08) 68 2.10 (1.17–3.79) 27 1.71 (0.87–3.38) 1.24 (0.73–2.09)
Trend p value 0.12 0.03 0.42 0.23
Drinking alcohol 
but not in the 
recent five years
71 231 0.88 (0.63–1.22) 115 0.92 (0.63–1.34) 51 0.80 (0.51–1.26) 1.14 (0.76–1.73)
ORs are from multivariable unconditional logistic regression models with the adjustment for race, age, education, first-degree breast cancer family 
history, age at menarche, gravidity, number of full-term pregnancies, BMI 1 year before reference date, COC use, the average number of alcoholic 
drinks per week in the recent 5 years, a variable combining menopausal status and hormone therapy use except where otherwise noted. BMI, body 
mass index; COC, combined oral contraceptive; CI, confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor. 
aModels did not include gravidity. bAge at first full-term pregnancy and duration of breastfeeding mutually adjusted for each other. cAlcohol drinking 
status during reference age replaced the number of alcoholic drinks per week in the recent 5 years in the models.
Table 2 (Continued)
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itive and receptor-negative cancers in our study were also
observed in previous studies among young [19,21] or premen-
opausal [12] parous women, although the associations were
not statistically significant in two of these studies [12,19]. The
magnitude of the protective effects of breastfeeding was
larger in our study than was reported from previous studies.
Three [12,20,22] of four previous studies also found no asso-
ciation between OC use and ER+PR+ or ER-PR- breast cancer
among young [19,20] or premenopausal women [12,22]; the
only inconsistent study found a marginally statistically signifi-
cant increased risk of ER- PR- cancer among women who had
ever used oral contraceptives [19].
It has been argued [10,12] that if certain hormone-related fac-
tors predominantly act through estrogen and progesterone
mediated by their respective receptors, then these hormone-
related factors will be associated with hormone receptor-pos-
itive, but not with receptor-negative, breast cancer. Our find-
ings that increasing number of full-term pregnancies is
associated with lower risk of ER+PR+  cancer, whereas
increasing recent average weekly alcohol consumption is
associated with greater risk, and that ER- PR- cancers are not
affected by these risk factors, support the hypothesis that
these factors act predominantly through this type of hormonal
mechanism.
In contrast, it could be hypothesized that hormonal factors
should affect receptor-positive and receptor-negative breast
cancer similarly. It has been hypothesized that an ER- stem cell
population gives rise to ER+ progenitor cells [40], which will
proliferate when exposed to estrogen, but can also send para-
crine signals that will cause neighboring populations of ER-
cells to proliferate. Thus, late age at menarche and breastfeed-
ing may still act through hormonal mechanisms that involve ER
and PR, but our results suggest that the exact mechanism dif-
fers from that involved in the effect of parity and alcohol con-
sumption.
One strength of our study is the large number of case patients
included. Our analysis included more young breast cancer
patients than six of the eight previously published studies with
results for ER/PR status among women under the age of 50
years [19-21,36] or among premenopausal women
[12,22,33,37]. For the only two studies with a larger sample
size, one focused exclusively on alcohol consumption [36] and
the other focused on reproductive factors including parity, age
at first full-term pregnancy, and breastfeeding [21].
Several limitations of this study must also be considered. The
number of control subjects in this study was relatively small.
This could explain why we detected a similar magnitude of
effect for late first full-term pregnancy on ER+PR+ cancer as
the Women's CARE Study [21], but in our study it did not
reach statistical significance because of our limited statistical
power. This could also explain why our case–case analyses
suggested that the effect of late age at first full-term pregnancy
and BMI differed significantly between the ER+PR+ and the
ER- PR- case patients, whereas we did not detect any statisti-
cally significant associations when comparing each of the sub-
types with the control subjects.
Because of our decision not to retain the case–control match
during data analyses, we used an unconditional instead of a
conditional logistic regression approach, which could have
biased our relative risk estimates toward the null value, as
described by Rothman and Greenland [29]. However, in com-
parison with the data from the Women's CARE Study [21],
which has so far been the largest population-based case–con-
trol study of women aged 35 to 64 years, we found similar
results for parity and breastfeeding, whereas the positive asso-
ciation between late first full-term pregnancy and ER+PR+ can-
cer was statistically significant in the Women's CARE Study
but not in ours. In comparison with the prospective data from
the Nurses' Health Study [18] for both premenopausal and
postmenopausal women, our results for age at menarche and
parity were consistent with theirs, but our results for late first
full-term pregnancy were not. In addition, our overall findings
for all the hormone-related factors we examined are quite sim-
ilar to those in the literature for young or premenopausal
women.
We have no data on the methods and cutoff points for recep-
tor status used by each laboratory because we obtained this
information from the CSP, which bases its classifications on
information in pathology reports from a variety of laboratories.
Although we assume that most laboratories used immunohis-
tochemistry assays and consistent cutoff points, it is possible
that some laboratories used different methods or different cut-
off points. However, we believe that any such inconsistencies
would be unlikely to cause the observed associations and, if
anything, that they would bias our relative risk estimates
toward the null value.
Another limitation is that in our analyses by receptor subtypes,
we excluded 21% of our case patients, because 16% of
patients had no ER or PR status information and 5% were bor-
derline positives or undecided for either ER or PR. The per-
centage of case patients without information from the cancer
registry in this study (16%) is similar to that reported by previ-
ous studies conducted within the SEER registries [21,28]. It is
unclear why some case patients do not have a known ER/PR
status. We observed that, in this study, the case patients with
known ER/PR status information were somewhat younger,
were better educated, gave birth later, and were more likely to
breastfeed than those whose ER/PR status had not been
determined. These differences between case patients with
known ER/PR status and those without ER/PR information
from the CSP could have biased our case–control comparison
by receptor subtypes and caused us to find an effect of late
age at first full-term pregnancy even if none existed, but wouldAvailable online http://breast-cancer-research.com/content/8/4/R39
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tend to underestimate any protective effect of breastfeeding
on breast cancer risk. It is unlikely that this bias would be dif-
ferent for ER+PR+ and ER- PR- cancer. Furthermore, this would
not have influenced our case–control analysis using all case
patients combined. Because our results from the case–case
and the case–control analysis by receptor subtypes or using
all case patients combined were generally consistent, we think
it unlikely that these issues caused important bias in this study.
Conclusion
Our results suggest that the number of full-term pregnancies
and recent alcohol consumption affect breast cancer risk in
young women predominantly through estrogen and progester-
one mediated by their respective receptors. Late age at
menarche and breastfeeding may protect against breast can-
cer through a different hormonal mechanism.
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